Cargando…

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)

BACKGROUND: Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical cannabis products. Regulatory data indicate an increase in the prescription of medicinal cannabis since 2019, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lintzeris, Nicholas, Mills, Llewellyn, Abelev, Sarah V., Suraev, Anastasia, Arnold, Jonathon C., McGregor, Iain S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338505/ https://www.ncbi.nlm.nih.gov/pubmed/35907959 http://dx.doi.org/10.1186/s12954-022-00666-w

Ejemplares similares

Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey
por: Suraev, Anastasia, et al.
Publicado: (2023)

Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey
por: Arkell, Thomas R., et al.
Publicado: (2023)

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
por: Lintzeris, Nicholas, et al.
Publicado: (2020)

Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile
por: Swift, Wendy, et al.
Publicado: (2013)

The “Next Day” Effects of Cannabis Use: A Systematic Review
por: McCartney, Danielle, et al.
Publicado: (2023)

Prescribing medicinal cannabis
por: Arnold, Jonathon C, et al.
Publicado: (2020)

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey
por: Karanges, Emily A, et al.
Publicado: (2018)

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients
por: Benson, Melissa J, et al.
Publicado: (2020)

Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
por: Mills, Llewellyn, et al.
Publicado: (2022)

Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease
por: Benson, Melissa J, et al.
Publicado: (2020)

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years
por: MacPhail, Sara L., et al.
Publicado: (2022)

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials
por: Arkell, Thomas R., et al.
Publicado: (2021)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
por: Heblinski, Marika, et al.
Publicado: (2020)

Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ(9)-THC at Human CB(1) and CB(2) Receptors
por: Santiago, Marina, et al.
Publicado: (2019)

A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function
por: Milligan, Carol J., et al.
Publicado: (2022)

Detection of Δ(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
por: Arkell, Thomas R., et al.
Publicado: (2019)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
por: Jackson, Melissa A., et al.
Publicado: (2021)

Cannabis Consumers’ View of Regulated Access to Recreational Cannabis: A Multisite Survey in Switzerland
por: Müller, Monika, et al.
Publicado: (2023)

Cannabis Users' Recommended Warnings for Packages of Legally Sold Cannabis: An Australia-Centered Study
por: Malouff, John M., et al.
Publicado: (2016)

Consumer perceptions of strain differences in Cannabis aroma
por: Gilbert, Avery N., et al.
Publicado: (2018)

The Rise and Rise of Medicinal Cannabis, What Now? Medicinal Cannabis Prescribing in Australia 2017–2022
por: Hallinan, Christine Mary, et al.
Publicado: (2022)

Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome
por: Anderson, Lyndsey L., et al.
Publicado: (2022)

Can cannabis kill? Characteristics of deaths following cannabis use in England (1998–2020)
por: Rock, Kirsten L, et al.
Publicado: (2022)

20. Integrating Cannabis Into Clinical Care
por: Abrams, Donald
Publicado: (2013)

Trends in cannabis use intention around the period of cannabis legalisation in Australia: An age‐period‐cohort model
por: Chiu, Vivian, et al.
Publicado: (2022)

Investigating Relationships Between Alcohol and Cannabis Use in an Online Survey of Cannabis Users: A Focus on Cannabinoid Content and Cannabis for Medical Purposes
por: Karoly, Hollis C., et al.
Publicado: (2020)

Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021–2022 survey
por: Bawa, Zeeta, et al.
Publicado: (2022)

Cannabis Indica—Cannabis Americana
por: Williams, Charles
Publicado: (1897)

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)
por: Mersiades, Antony J, et al.
Publicado: (2018)

Navigating the grey: Experiences of incremental cannabis reform in Australia
por: Barrett, Liz, et al.
Publicado: (2022)

Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
por: Cairns, Elizabeth A., et al.
Publicado: (2023)

Aggressive Driving Behaviours in Cannabis Users. The Influence of Consumer Characteristics
por: Ortiz-Peregrina, Sonia, et al.
Publicado: (2021)

Prevalence of anxiety and depression among engineering students consuming cannabis
por: Vaziri-harami, Roya, et al.
Publicado: (2022)

Compliance With Cannabis Act Regulations Regarding Online Promotion Among Canadian Commercial Cannabis-Licensed Firms
por: Sheikhan, Natasha Y., et al.
Publicado: (2021)

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
por: Anderson, Lyndsey L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g0ncjr7bladu8l2oamvg0s1qu2